In pancreatic carcinoma, AGR2 expression is related to the response to gemcitabine [60], and in an animal model, blocking monoclonal antibodies against AGR2 and C4.4A resulted in the regression of tumor invasion and increased survival [61]. The gene discussed is LYPD3; the disease is exocrine pancreatic carcinoma.